Samm50 Downregulation-Driven Mitochondrial Dysfunction Triggers Ferroptosis and Contributes to Ketamine-Induced Neurotoxicity and Cognitive Impairment.
Yuanlong Li, Xiangyun Dai, Junmei Hu, Yunke Zuo, Yi Li, Zhongjie Sun, Zhilin Jia, Xia Wang, Peipei Wang, Linchuan Liao
Neuropharmacology September 18, 2026 DOI: 10.1016/j.neuropharm.2026.111192 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical study using a mouse model and cell line Peer reviewed |
|---|---|
| Population | Mice with ketamine-induced cognitive impairment and HT22 hippocampal neuronal cells |
| Interventions | Ketamine Fer-1 deferoxamine (DFO) MitoQ Samm50 overexpression |
| Topics | Ketamine Esketamine |
| Keywords | Cognitive impairment Ferroptosis Hippocampal neurotoxicity Mitochondrial dysfunction Samm50 |
| Key points | The authors propose that ketamine first downregulates Samm50, causing mitochondrial dysfunction (energy failure and oxidative stress), which then triggers ferroptosis via iron accumulation and suppression of GPX4/SLC7A11. Samm50 overexpression restored mitochondrial function and upregulated GPX4 and SLC7A11, ameliorating ferroptosis, which the authors present as evidence that Samm50 is a critical upstream link and a potential therapeutic target. |
Abstract
Ketamine abuse is associated with persistent cognitive deficits and neurotoxicity, though the underlying mechanisms remain incompletely understood. While mitochondrial dysfunction and ferroptosis have been separately implicated, their causal relationship and the key molecular link in ketamine-induced hippocampal damage are unclear. Using a mouse model of ketamine-induced cognitive impairment and an HT22 hippocampal neuronal cell line, we found that ketamine significantly downregulated Samm50, a key protein maintaining mitochondrial outer membrane integrity, in both the hippocampus and HT22 cells. This downregulation was accompanied by reduced mitochondrial membrane potential (MMP) and ATP levels, and elevated reactive oxygen species (ROS). Concurrently, ketamine upregulated transferrin receptor TFR1, led to Fe2+/Fe3+ accumulation, increased malondialdehyde (MDA) and lipid peroxidation (LPO), and decreased the ferroptosis regulators GPX4 and SLC7A11. In vitro, ferroptosis inhibitors Fer-1 and deferoxamine (DFO) reversed ketamine-induced cell death, Fe2+ overload, LPO, and MMP loss, but Fer-1 failed to restore ATP or Samm50 expression. MitoQ rescued ATP, MMP, and ROS. Strikingly, Samm50 overexpression not only restored mitochondrial function (ATP, MMP, ROS) but also upregulated GPX4 and SLC7A11, thereby ameliorating ferroptosis. Collectively, ketamine induces hippocampal neurotoxicity and cognitive impairment via a two-step mechanism: it first downregulates Samm50, leading to primary mitochondrial dysfunction (energy failure and oxidative stress); this mitochondrial impairment then triggers ferroptosis through iron accumulation and suppression of GPX4/SLC7A11. Samm50 downregulation serves as a critical upstream event linking mitochondrial dysfunction to ferroptosis, representing a novel therapeutic target for ketamine-induced neuropsychiatric toxicity.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
State of the evidence: Ketamine Opposes
Ketamine downregulated Samm50, causing mitochondrial dysfunction that triggered ferroptosis via iron accumulation and suppression of GPX4/SLC7A11, contributing to hippocampal neurotoxicity and cognitive impairment.
Synthesized
Comparable studies
Other preclinical and animal studies on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Rats | 2010 | Observational study | |
| Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Conscious rats | 1997 | Dose-response study with microdialysis and behavioral testing | |
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites Mice | 2016 | Preclinical study | |
| The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate Spinal neurons in decerebrate or pentobarbitone-anaesthetized cats and rats | 1983 | Experimental study | |
| R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Mice | 2015 | Experimental study |
Citations in the library
Cites 8
- Reviewing the ketamine model for schizophrenia Journal of Psychopharmacology November 20, 2013
- Ketamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions CNS Neuroscience & Therapeutics April 12, 2013
- Metabolism and metabolomics of ketamine: a toxicological approach Forensic Sciences Research January 2, 2017
- The amino acid metabolism pathway of peripheral T lymphocytes and ketamine-induced schizophrenia-like phenotype. Journal of Psychiatry and Neuroscience 2024
- The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging health threats journal April 15, 2011
and 3 more in the library